Christian Theilacker
Overview
Explore the profile of Christian Theilacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Grant L, Begier E, Theilacker C, Barry R, Hall-Murray C, Yan Q, et al.
J Infect Dis
. 2023 Sep;
229(1):282-293.
PMID: 37665210
Background: Nonbacteremic community-acquired pneumonia (CAP) is a leading presentation of severe pneumococcal disease in adults. Serotype-specific urinary antigen detection (UAD) assay can detect serotypes causing pneumococcal CAP, including nonbacteremic cases,...
12.
Grant L, Slack M, Theilacker C, Vojicic J, Dion S, Reinert R, et al.
Vaccine
. 2023 Aug;
41(38):5662-5669.
PMID: 37544825
Background: Neither indirect protection through use of 13-valent and 10-valent pneumococcal conjugate vaccines (PCV13 and PCV10) in pediatric National Immunization Programs (NIPs) nor direct vaccination with the 23-valent polysaccharide vaccine...
13.
Ankert J, Hagel S, Schwarz C, Pan K, Wang L, von Eiff C, et al.
ERJ Open Res
. 2023 Jun;
9(3).
PMID: 37260459
https://bit.ly/3JMlwFt.
14.
Dunne E, Nunes M, Slack M, Theilacker C, Gessner B
Pneumonia (Nathan)
. 2023 May;
15(1):10.
PMID: 37226198
Pneumococcal conjugate vaccines (PCVs) provide protection against vaccine-type pneumococcal disease in both children and adults. Growing evidence suggests that PCVs also reduce pneumonia and lower respiratory tract infections (LRTIs) more...
15.
Hansen K, Runow E, Torisson G, Theilacker C, Palmborg A, Pan K, et al.
Front Public Health
. 2023 Mar;
11:1086648.
PMID: 36875379
Objectives: In Sweden, pneumococcal serotype distribution in adults with community-acquired pneumonia (CAP) and potential coverage of currently licensed pneumococcal conjugate vaccines (PCVs) is unknown. Methods: During 2016-2018, patients aged ≥18...
16.
Horn M, Theilacker C, Sprenger R, von Eiff C, Mahar E, Schiffner-Rohe J, et al.
PLoS One
. 2023 Feb;
18(2):e0281261.
PMID: 36791091
Introduction: Two next-generation pneumococcal conjugate vaccines (PCVs), a 15- and a 20-valent PCV (PCV15 and PCV20), have recently been licensed for use in adults, and PCV15 has also been licensed...
17.
Dunne E, Cilloniz C, von Mollendorf C, Lewnard J, Grant L, Slack M, et al.
Arch Bronconeumol
. 2023 Jan;
59(3):157-164.
PMID: 36681604
Introduction: Fifteen and 20-valent pneumococcal conjugate vaccines (PCV15; PCV20) were recently licensed to prevent pneumococcal disease in adults. In the absence of efficacy or effectiveness data for these new vaccines,...
18.
Orsi A, Domnich A, Mosca S, Ogliastro M, Sticchi L, Prato R, et al.
Microorganisms
. 2023 Jan;
11(1).
PMID: 36677362
Pneumococcal community-acquired pneumonia (CAP) is a leading cause of mortality. Following the introduction of pneumococcal conjugate vaccines (PCVs) in children, a decrease in the burden of the disease was reported....
19.
Davies L, Cizmeci D, Guo W, Luedemann C, Alexander-Parrish R, Grant L, et al.
Sci Transl Med
. 2022 Aug;
14(656):eabm4065.
PMID: 35921476
is a major cause of community-acquired pneumonia, bacteremia, and meningitis in older adults worldwide. Two pneumococcal vaccines containing capsular polysaccharides are in current use: the polysaccharide vaccine PPSV23 and the...
20.
Robinson R, Mitsi E, Nikolaou E, Pojar S, Chen T, Reine J, et al.
Am J Respir Crit Care Med
. 2022 Jul;
206(11):1379-1392.
PMID: 35802840
serotype 3 (SPN3) is a cause of invasive pneumococcal disease and associated with low carriage rates. Following the introduction of pediatric 13-valent pneumococcal conjugate vaccine (PCV13) programs, SPN3 declines are...